Member Info for HarChris

Cystic fibrosis? I think you need to do a little research of your own!

But it's all this theorising that is damaging on here and questioning the motives of every well intentioned member. So ShaunP didn't post on the morning of results and that makes him a shorter does it? Or that he sold out? It's just stupid talk.

I remember when I was heavily invested here a few months ago and the bb became hysterical after the independent article. ShaunP popped on a few hours later, didn't even engage with the story and just carried on researching as usual. That really helped me to relax and see the bigger picture.

Now VanV who's done more for novacyt than any other member on here is having to reject claims that he sold out and has some ulterior motive. It's really poor form.

Some really stupid comments on here failing to grasp what VanV is saying. What on earth are you talking about MS? Accepting failure? What power do a handful of novacyt holders have over the wants of the government???

He is simply pointing out that whether you like it or not, whether it's the right thing or not, the government are not going to turn their backs on LFTs at this stage.

ShaunP was driven away from this bb, are people trying to drive VanV away too? Perhaps everyone should sign a 'this share wil be £100 by March' disclaimer before being allowed to post?

Why so many big sellers? I wasn't aware there were any?
Imo there's still two-three weeks for traders to sell out elsewhere and settle in for results.

The risk/reward here is amazing. Even if covid revenue were to drop considerably come the summer you are looking at a business with probably £180m in cash and relatively tiny on going expenditure that has the money to not only respond to the post-covid world but potentially play a part in shaping it.

Last week when the share price was between about 172 and 177 millions went through at 178/179. I think we calculated about 14 million shares in all, so 7% of the company. The last few days it's a little more difficult to tell so yeah the buyer might be finished now but still expect a TR1 from last week and prior to that.

Foodforthought, those moaning about the lack of a TR1 have a legitimate reason to do so. Today's delayed trades are nothing compared to some days over the past week or so. We've seen three, four, five million buys put through after hours on a few occasions now in blocks of 20k, 30k and sometimes 50k and I suppose in part that is reflected in the share price (sp is 15% up over the past two weeks) but a buyer, or even two, must be building a sizeable holding. It could conceivably be a couple of international parties buying that have kept just under the international threshold of 5% but more likely they just haven't filed the TR1 on time.

From my very limited experience of trading, what I've learnt is traders are very switched on with timelines and tend to pile in *very* close to when the action is about to happen. There is little chance of any results this week or even next so although I too am surprised we're still around £1.90 it does not mean this won't suddenly move much, much higher late Feb to early March.

What our esteemed investment bank cleaner has been saying isn't exactly wrong, it's just annoying that we were being told it by an illiterate amateur that couldn't seem to understand that we aren't interested in chasing gains left, right and centre. We have invested in synairgen and we are happy to take our position early and wait to see how it all plays out.

Just bought back in after selling out completely the other Friday. I never planned to exit ncyt but was very disappointed with the trading update. Expectation was too great after leaving us in the dark for six months with many, none more than me, defending his strategy robustly, so to then give such a flimsy forward statement was imo, not good enough to keep the share price where it was. I try to invest in ethical companies but if I think the share price is to tumble I'm going to sell and reassess afterwards...

Anyway it's nice to have a person in charge who is focused on long term shareholder value and making something of this business. I am a bit out of the loop but am still of the same opinion that I was a month ago, that this has the makings of a midcap company in the next two to three years.

Thanks to your recommendation earlier I moved everything into Arb at £2.50 as you advised me to and promised £3 by the end of the week. Should I be worried? I'm very scared and feel physically sick to see it drop. Please answer asap!!!

I reckon so, or maybe even lemsip.

I'm not sure how to pronounce it to be honest, should I emphasise the 'air' ?

For now synairgen's only competitor is itself - if approved everyone makes good money from here.

Kevin, I don't know for sure they are sells but the price appears to be between 189 and 191 for all of them. My guess is they're sells and the buyer will be back scooping them up a little cheaper than they'd have paid today (195 ish today)

I think most of those are sells... if the past month is anything to go by the loading up seems to take a backseat when an rns lands. The following day the price is walked down a little and the buying restarts.

Exactly, it would be a real shock to see a £100k director purchase from Holgate out of the blue at this stage!

Because the likes of Holgate, Djukanovic and even Richard probably aren't that wealthy. Bringing this drug to market and eventually realising their profits when the company is sold would likely make them rich beyond their wildest dreams...

You're in a very loving mood Woodstock - did you get to join in with your lady and her friend for valentine's?!

That's not true, phase 3 is very much about efficacy. We know it was shown to work in the smaller trial, we just need to match that across more people and geographies now...

The posters like Happy simply do not understand the value in covid therapeutics. They look at vaccine effectiveness, vaccine take-up, they look at the size of the market, they multiple that by the likely price and come to some figure. That's not the world we are living in. The threat of future waves, vaccine evading mutations etc is enormous and costs potentially trillions of pounds. This adds an extraordinary amount of value to any company that has a tool to fight this threat.

I've mentioned many examples of companies that are producing treatments and the effect it's had on their share price. Another amazing example is Eli Lilly. Check it out, share price took off around the same time as getting approval for their monoclonal antibody treatment - 45% rise in the past few months. That might not seem like much but when you then realise that is an increase of almost $60b you start to realise just how lucrative this might be for little synairgen..